Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline and ACT for Smoking Cessation in Serious Mental Illness
NCT04011280Phase 4
Key facts
- Status
- Completed
- Start
- Aug 2019
- Primary completion
- Mar 2022
- Countries
- 1
- Sponsor
- University of California, San Diego
- Modality
- Small Molecules
- Drugs
- varenicline
- Conditions
- nicotine dependence
01
Overview
Phase 4, randomised, double-blind trial of varenicline in nicotine dependence (2 arms), sponsored by University of California, San Diego. Primary endpoint: Feasibility of Combining ACT With 2 Different Varenicline-assisted Quitting Strategies at 24 weeks. Started Aug 2019; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Low Dose Varenicline
0.5 mg twice daily with slower titration
Standard Dose Varenicline
1.0 mg twice daily with standard titration
03
Who it enrols
Smokers with bipolar disorder or schizophrenia spectrum disorder motivated to quit.
04
Endpoints
Primary
Feasibility of Combining ACT With 2 Different Varenicline-assisted Quitting Strategies
Beyond the preview
Go deeper on NCT04011280.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04011280.